Balasubramanyam Karanam to Ovarian Neoplasms
This is a "connection" page, showing publications Balasubramanyam Karanam has written about Ovarian Neoplasms.
Connection Strength
0.412
-
Anchoori RK, Anchoori V, Lam B, Tseng SH, Das S, Velasquez FC, Karanam B, Poddatoori D, Patnam R, Rudek MA, Chang YN, Roden RBS. Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor. PLoS One. 2023; 18(6):e0285221.
Score: 0.174
-
Anchoori RK, George L, Tseng SH, Lam B, Polkampally S, Amiano AD, Foran P, Tsingine H, Samanapally H, Carrizo Velasquez F, Das S, Xing D, Bin Salam A, Karanam B, Hung CF, Roden RBS. Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors. PLoS One. 2021; 16(9):e0256937.
Score: 0.154
-
Kamiyama H, Rauenzahn S, Shim JS, Karikari CA, Feldmann G, Hua L, Kamiyama M, Schuler FW, Lin MT, Beaty RM, Karanam B, Liang H, Mullendore ME, Mo G, Hidalgo M, Jaffee E, Hruban RH, Jinnah HA, Roden RB, Jimeno A, Liu JO, Maitra A, Eshleman JR. Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res. 2013 Mar 01; 19(5):1139-46.
Score: 0.085